MX2014004359A - Proteina naglu humana recombinante y usos de la misma. - Google Patents
Proteina naglu humana recombinante y usos de la misma.Info
- Publication number
- MX2014004359A MX2014004359A MX2014004359A MX2014004359A MX2014004359A MX 2014004359 A MX2014004359 A MX 2014004359A MX 2014004359 A MX2014004359 A MX 2014004359A MX 2014004359 A MX2014004359 A MX 2014004359A MX 2014004359 A MX2014004359 A MX 2014004359A
- Authority
- MX
- Mexico
- Prior art keywords
- proteins
- naglu
- mixture
- recombinant human
- human naglu
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- 239000013598 vector Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 125000000311 mannosyl group Chemical class C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546248P | 2011-10-12 | 2011-10-12 | |
| PCT/US2012/059708 WO2013055888A2 (en) | 2011-10-12 | 2012-10-11 | Recombinant human naglu protein and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014004359A true MX2014004359A (es) | 2014-05-28 |
Family
ID=48082738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004359A MX2014004359A (es) | 2011-10-12 | 2012-10-11 | Proteina naglu humana recombinante y usos de la misma. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9579366B2 (enExample) |
| EP (1) | EP2766477B1 (enExample) |
| JP (1) | JP6329483B2 (enExample) |
| KR (1) | KR20140108519A (enExample) |
| CN (1) | CN103958676A (enExample) |
| AU (1) | AU2012322811A1 (enExample) |
| BR (1) | BR112014008873A2 (enExample) |
| CA (1) | CA2852027A1 (enExample) |
| CL (1) | CL2014000927A1 (enExample) |
| CO (1) | CO7010783A2 (enExample) |
| HK (1) | HK1200489A1 (enExample) |
| IL (1) | IL232073A0 (enExample) |
| IN (1) | IN2014MN00740A (enExample) |
| MX (1) | MX2014004359A (enExample) |
| RU (1) | RU2014117291A (enExample) |
| SG (2) | SG10201510106PA (enExample) |
| TW (1) | TW201321515A (enExample) |
| WO (1) | WO2013055888A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497246B2 (en) | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| JP5901877B2 (ja) | 2007-07-27 | 2016-04-13 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物 |
| ES2725200T3 (es) | 2009-10-09 | 2019-09-20 | Armagen Inc | Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC |
| NZ715014A (en) | 2010-09-09 | 2018-10-26 | Synageva Biopharma Corp | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| WO2012112681A1 (en) | 2011-02-15 | 2012-08-23 | Shire Human Genetic Therapies, Inc. | Methods for treating lysosomal acid lipase deficiency |
| AU2012322811A1 (en) * | 2011-10-12 | 2014-05-01 | Synageva Biopharma Corp. | Recombinant human NaGlu protein and uses thereof |
| EP4338797A3 (en) | 2011-12-02 | 2024-06-12 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
| CA2912678C (en) | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| TWI793159B (zh) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
| KR102446169B1 (ko) * | 2014-05-14 | 2022-09-22 | 에스테베 파마슈티칼스 에스에이 | 리소좀 저장 장애의 치료를 위한 아데노연관 바이러스 벡터 |
| US20170267986A1 (en) * | 2014-06-25 | 2017-09-21 | Shire Human Genetic Therapies, Inc. | Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase |
| BR112017002741A2 (pt) | 2014-08-11 | 2018-02-27 | Shire Human Genetic Therapies, Inc | peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas |
| AU2015323966A1 (en) | 2014-09-29 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating mucopolysaccharidosis IIIB (MPSIIIB) |
| CN104524662B (zh) * | 2014-12-31 | 2017-02-22 | 迈得医疗工业设备股份有限公司 | 一种医用针座组装的上料机构 |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| US20190083583A1 (en) * | 2016-01-29 | 2019-03-21 | Alexion Pharmaceuticals, Inc. | Enzyme replacement therapy in mucopolysaccharidosis iiib patients |
| WO2017181113A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsyvania | Gene therapy for treating mucopolysaccharidosis type ii |
| US10633705B2 (en) * | 2016-10-14 | 2020-04-28 | Alexion Pharmaceuticals, Inc. | N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods |
| WO2019060662A1 (en) | 2017-09-22 | 2019-03-28 | The Trustees Of The University Of Pennsylvania | GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
| WO2021194915A1 (en) * | 2020-03-23 | 2021-09-30 | The University Of North Carolina At Chapel Hill | Aav-naglu vectors for treatment of mucopolysaccharidosis iiib |
| CN111718947B (zh) * | 2020-06-18 | 2022-08-23 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
| US5897998A (en) | 1997-08-04 | 1999-04-27 | The University Of Georgia Research Foundation, Inc. | Method for manipulating avian eggs |
| US7511120B2 (en) | 1997-10-16 | 2009-03-31 | Synageva Biopharma Corp. | Glycosylated G-CSF obtained from a transgenic chicken |
| JP2001520009A (ja) | 1997-10-16 | 2001-10-30 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | 鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター |
| US20040019923A1 (en) | 1997-10-16 | 2004-01-29 | Ivarie Robert D. | Exogenous proteins expressed in avians and their eggs |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US6679165B2 (en) | 2002-05-22 | 2004-01-20 | Shiny Shih | Window adapted to a dater |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| EP1587923B1 (en) * | 2003-01-22 | 2011-08-24 | Duke University | Improved constructs for expressing lysosomal polypeptides |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050090001A1 (en) | 2003-10-07 | 2005-04-28 | Parker Stephen H. | Cell lines and methods for producing proteins |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| US20090166224A1 (en) * | 2004-05-05 | 2009-07-02 | Ziping Yang | Multi-lectin affinity chromatography and uses thereof |
| EP1981546B1 (en) | 2006-02-06 | 2014-06-04 | The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center | Enzyme replacement therapy for treating lysosomal storage diseases |
| CN101410408A (zh) | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | 用于浓缩多肽的方法 |
| CA2671570A1 (en) | 2007-01-26 | 2008-07-31 | Synageva Biopharma Corp. | Transgene expression in avians |
| US8431770B2 (en) * | 2008-01-07 | 2013-04-30 | Synageva Biopharma Corp. | Method of producing sialytransferase-modified proteins |
| WO2009131698A2 (en) * | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
| ES2576853T3 (es) * | 2009-07-03 | 2016-07-11 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes |
| UA115648C2 (uk) * | 2010-06-25 | 2017-12-11 | Шае Хюмен Дженетік Терапіс, Інк. | Доставка терапевтичних агентів до цнс |
| NZ702801A (en) | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
| WO2012012742A2 (en) * | 2010-07-22 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Crystal structure of human alpha-n-acetylglucosaminidase |
| NZ715014A (en) | 2010-09-09 | 2018-10-26 | Synageva Biopharma Corp | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| AU2012322811A1 (en) * | 2011-10-12 | 2014-05-01 | Synageva Biopharma Corp. | Recombinant human NaGlu protein and uses thereof |
-
2012
- 2012-10-11 AU AU2012322811A patent/AU2012322811A1/en not_active Abandoned
- 2012-10-11 US US13/649,595 patent/US9579366B2/en not_active Expired - Fee Related
- 2012-10-11 CN CN201280049876.4A patent/CN103958676A/zh active Pending
- 2012-10-11 JP JP2014535865A patent/JP6329483B2/ja not_active Expired - Fee Related
- 2012-10-11 IN IN740MUN2014 patent/IN2014MN00740A/en unknown
- 2012-10-11 WO PCT/US2012/059708 patent/WO2013055888A2/en not_active Ceased
- 2012-10-11 RU RU2014117291/10A patent/RU2014117291A/ru not_active Application Discontinuation
- 2012-10-11 BR BR112014008873-0A patent/BR112014008873A2/pt not_active Application Discontinuation
- 2012-10-11 CA CA2852027A patent/CA2852027A1/en not_active Abandoned
- 2012-10-11 SG SG10201510106PA patent/SG10201510106PA/en unknown
- 2012-10-11 EP EP12840612.1A patent/EP2766477B1/en not_active Not-in-force
- 2012-10-11 KR KR1020147012617A patent/KR20140108519A/ko not_active Ceased
- 2012-10-11 US US14/350,644 patent/US20140255383A1/en not_active Abandoned
- 2012-10-11 SG SG11201401457SA patent/SG11201401457SA/en unknown
- 2012-10-11 MX MX2014004359A patent/MX2014004359A/es unknown
- 2012-10-11 HK HK15100907.5A patent/HK1200489A1/xx unknown
- 2012-10-12 TW TW101137865A patent/TW201321515A/zh unknown
-
2014
- 2014-04-10 IL IL232073A patent/IL232073A0/en unknown
- 2014-04-11 CL CL2014000927A patent/CL2014000927A1/es unknown
- 2014-05-08 CO CO14098853A patent/CO7010783A2/es unknown
-
2017
- 2017-02-10 US US15/429,309 patent/US20170216412A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014008873A2 (pt) | 2020-09-15 |
| SG10201510106PA (en) | 2016-01-28 |
| US9579366B2 (en) | 2017-02-28 |
| NZ623690A (en) | 2016-08-26 |
| WO2013055888A3 (en) | 2013-06-13 |
| CN103958676A (zh) | 2014-07-30 |
| RU2014117291A (ru) | 2015-11-20 |
| US20170216412A1 (en) | 2017-08-03 |
| CA2852027A1 (en) | 2013-04-18 |
| CO7010783A2 (es) | 2014-07-31 |
| WO2013055888A2 (en) | 2013-04-18 |
| AU2012322811A1 (en) | 2014-05-01 |
| KR20140108519A (ko) | 2014-09-11 |
| EP2766477B1 (en) | 2018-09-26 |
| HK1200489A1 (en) | 2015-08-07 |
| IN2014MN00740A (enExample) | 2015-05-22 |
| CL2014000927A1 (es) | 2014-11-14 |
| US20140255383A1 (en) | 2014-09-11 |
| JP2014534962A (ja) | 2014-12-25 |
| JP6329483B2 (ja) | 2018-05-23 |
| IL232073A0 (en) | 2014-05-28 |
| US20130095092A1 (en) | 2013-04-18 |
| TW201321515A (zh) | 2013-06-01 |
| SG11201401457SA (en) | 2014-05-29 |
| EP2766477A4 (en) | 2015-07-15 |
| EP2766477A2 (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014004359A (es) | Proteina naglu humana recombinante y usos de la misma. | |
| PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
| EP2470559A4 (en) | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| TW201613954A (en) | Interleukin-10 fusion proteins and uses thereof | |
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| WO2011123830A3 (en) | Alpha 1-antitrypsin compositions and methods of making and using same | |
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| MX2013004726A (es) | Anticuerpos dkk1 y metodos de uso. | |
| MY175708A (en) | Dna antibody constructs and method of using same | |
| MX351565B (es) | Colageno 7 y metodos relacionados. | |
| NZ616989A (en) | Therapeutic nuclease compositions and methods | |
| PH12022550693A1 (en) | Multi-specific binding proteins for cancer treatment | |
| IN2014CN04586A (enExample) | ||
| MD4548B1 (ro) | Polipeptide care se leagă de CX3CR1 | |
| EA201190326A1 (ru) | Полипептиды гормона роста и способы их получения и применения | |
| MX364623B (es) | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. | |
| MX2011012039A (es) | Anticuerpos bloqueadores anti-dkk-1 y sus usos. | |
| TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
| MX2018015110A (es) | Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos. | |
| EP4446410A3 (en) | Compositions comprising polypeptides having galactanase activity and polypeptides having beta-galactosidase activity | |
| MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
| IN2012DN03358A (enExample) | ||
| WO2015108856A3 (en) | Methods for enhancing the delivery of active agents |